BNP Paribas Arbitrage SA lifted its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 58.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,005 shares of the medical instruments supplier’s stock after buying an additional 6,287 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in OraSure Technologies were worth $294,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in OSUR. Victory Capital Management Inc. purchased a new position in shares of OraSure Technologies in the first quarter worth $100,000. First Mercantile Trust Co. purchased a new position in shares of OraSure Technologies in the second quarter worth $104,000. Private Advisor Group LLC lifted its holdings in shares of OraSure Technologies by 7.1% in the first quarter. Private Advisor Group LLC now owns 10,923 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 723 shares in the last quarter. Profund Advisors LLC purchased a new position in shares of OraSure Technologies in the first quarter worth $137,000. Finally, Capital Fund Management S.A. purchased a new position in shares of OraSure Technologies in the first quarter worth $144,000. 92.10% of the stock is currently owned by hedge funds and other institutional investors.
Shares of OraSure Technologies, Inc. (NASDAQ OSUR) opened at 21.81 on Wednesday. The company’s 50-day moving average is $20.72 and its 200-day moving average is $16.18. The stock has a market cap of $1.30 billion, a P/E ratio of 40.31 and a beta of 1.57. OraSure Technologies, Inc. has a 1-year low of $7.09 and a 1-year high of $22.25.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. The company had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.07 EPS. Equities analysts expect that OraSure Technologies, Inc. will post $0.48 EPS for the current fiscal year.
In other OraSure Technologies news, SVP Jack E. Jerrett sold 73,463 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $20.77, for a total value of $1,525,826.51. Following the transaction, the senior vice president now owns 81,593 shares in the company, valued at approximately $1,694,686.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Douglas A. Michels sold 290,495 shares of the firm’s stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $16.75, for a total value of $4,865,791.25. Following the completion of the transaction, the chief executive officer now owns 894,012 shares in the company, valued at approximately $14,974,701. The disclosure for this sale can be found here. Insiders sold a total of 960,173 shares of company stock worth $18,752,210 in the last 90 days. 6.40% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/20/orasure-technologies-inc-osur-shares-bought-by-bnp-paribas-arbitrage-sa.html.
Several equities analysts have recently commented on the stock. Zacks Investment Research downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday. Canaccord Genuity reissued a “buy” rating and issued a $22.00 target price on shares of OraSure Technologies in a report on Tuesday. Jefferies Group LLC boosted their target price on shares of OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, June 28th. BidaskClub downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Stephens reissued an “overweight” rating and issued a $19.00 target price (up previously from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $17.88.
OraSure Technologies Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.